期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Analysis of the Role of D-Dimer,Interleukin-6,and Interleukin-18 in Differential Diagnosis of Pediatric Refractory Mycoplasma pneumoniae Pneumonia
1
作者 Yong Peng Aimin Li 《Journal of Clinical and Nursing Research》 2024年第7期118-122,共5页
Objective:To analyze the value of D-dimer(D-D),interleukin-6(IL-6),and IL-18 in the differential diagnosis of children with refractory Mycoplasma pneumoniae pneumonia(RMPP).Methods:The medical records of 92 children w... Objective:To analyze the value of D-dimer(D-D),interleukin-6(IL-6),and IL-18 in the differential diagnosis of children with refractory Mycoplasma pneumoniae pneumonia(RMPP).Methods:The medical records of 92 children with Mycoplasma pneumoniae pneumonia(MPP)treated in the hospital were selected for retrospective analysis from January 2023 to January 2024.After comprehensive examinations such as computed tomography examination of the chest,48 children with general Mycoplasma pneumoniae pneumonia(GMPP)were put in the GMPP group and 44 children with RMPP were grouped in the RMPP group.The IL-6,IL-18,and D-D levels were compared between the two groups,and the receiver operating characteristic(ROC)curves were plotted to analyze their value for differential diagnosis of RMPP.Results:The levels of IL-6,IL-18,and D-D in the RMPP group were higher than those in the GMPP group(P<0.05);the ROC curves showed that the specificity of the differential diagnosis of IL-6,IL-18,and D-D was higher,and their diagnostic value was significant.Conclusion:Determination of IL-6,IL-18,and D-D levels in children with MPP can further diagnose the children’s condition,which can help physicians formulate targeted treatment plans,and is of great significance to the improvement of the children’s condition,which is worthy of attention. 展开更多
关键词 refractory Mycoplasma pneumoniae pneumonia D-DIMER INTERLEUKIN-6 INTERLEUKIN-18 Differential diagnosis
下载PDF
Progression of anti-mycoplasma drug therapy in children with refractory mycoplasma pneumonia 被引量:4
2
作者 Haiyan Wu Xiang Zhang +3 位作者 Shanshan Ding Guohua Zhang Linlin Tang Lin Tang 《Journal of Chinese Pharmaceutical Sciences》 CAS CSCD 2022年第5期334-342,共9页
The incidence of refractory mycoplasma pneumoniae pneumonia(RMPP)in children is increasing year by year,and the disease is progressing rapidly.It is accompanied by serious complications and legacy effects,seriously af... The incidence of refractory mycoplasma pneumoniae pneumonia(RMPP)in children is increasing year by year,and the disease is progressing rapidly.It is accompanied by serious complications and legacy effects,seriously affecting the quality of life of children.The selection,dosage,and course of anti-MP drugs in children with RMPP have brought a lot of troubles to pediatric hospitals.In the present study,the characteristics,usage and dosage,drug resistance mechanism,and treatment progress of anti-MP drugs for the treatment of RMPP in children were reviewed.Collectively,our findings provided ideas for the treatment of children with RMPP using anti-MP drugs. 展开更多
关键词 CHILDREN refractory mycoplasma pneumonia Anti-mycoplasma drugs TREATMENT PROGRESSION
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部